Tabula Rasa HealthCare (TRHC) Posts Wider Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Tabula Rasa HealthCare Reports First Quarter 2022 Results
May 5, 2022 4:03 PM EDTFirst quarter 2022 revenue of $67.1 million from continuing operations includes CareVention HealthCare revenue of $66.3 million, up 19% vs. a year agoPlanned sales of PrescribeWellness, SinfonÃaRx, and DoseMe expected to add significant liquidity, reduce net debt, and provide financial flexibilityGAAP net loss from continuing operations of $20.4 millionAdjusted EBITDA of $2.5 million
MOORESTOWN, N.J., May 5, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC", the "Company," "we," "us," or "our") (Nasdaq: TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first... More
